Corcept Therapeutics Inc
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease. In February 2012, the company introduced Korlym ®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with endogenous hypercortisolism. Corcept is headquartered in Redwood City, California.
Generated $672.0 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$51.42
+10.53%GoodMoat Value
$16.61
67.7% overvaluedCorcept Therapeutics Inc (CORT) Stock Chart
CORT Interactive Stock Chart
Interactive stock chart for Corcept Therapeutics Inc (CORT) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.
Current price: $51.42. 52-week high: $90.32. 52-week low: $32.15. 50-day moving average: $39.31. 200-day moving average: $60.70.
Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for CORT. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Corcept Therapeutics Inc's investment potential.